Myelodysplastic Syndromes (Myelodysplastic Syndrome)

Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
Also Known As:
Myelodysplastic Syndrome; Hematopoetic Myelodysplasia; Dysmyelopoietic Syndrome; Hematopoetic Myelodysplasias; Myelodysplasia, Hematopoetic; Myelodysplasias, Hematopoetic; Syndrome, Dysmyelopoietic; Syndrome, Myelodysplastic; Syndromes, Dysmyelopoietic; Syndromes, Myelodysplastic; Dysmyelopoietic Syndromes
Networked: 5181 relevant articles (385 outcomes, 676 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
2. Anemia
3. Leukemia
4. BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
5. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)


1. Garcia-Manero, Guillermo: 82 articles (12/2015 - 01/2002)
2. Fenaux, Pierre: 78 articles (10/2015 - 01/2004)
3. Kantarjian, Hagop: 77 articles (09/2015 - 01/2002)
4. Deeg, H Joachim: 59 articles (09/2015 - 01/2002)
5. Cortes, Jorge: 55 articles (04/2015 - 07/2002)
6. Germing, Ulrich: 45 articles (12/2015 - 10/2002)
7. List, Alan F: 45 articles (03/2015 - 01/2006)
8. Faderl, Stefan: 44 articles (02/2015 - 08/2002)
9. Kantarjian, Hagop M: 41 articles (05/2015 - 05/2002)
10. Ravandi, Farhad: 41 articles (05/2015 - 02/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Myelodysplastic Syndromes:
1. Azacitidine (5 Azacytidine)FDA Link
11/01/2010 - "The earliest and the most successful epigenetic drug to date, 5-Azacytidine, is currently recommended as the first-line treatment of high-risk myelodysplastic syndromes (MDS). "
07/01/2013 - "These results demonstrate azacitidine benefit on overall survival compared with conventional care regimens in patients with higher-risk myelodysplastic syndromes who achieve hematologic response but never attain complete or partial remission, in addition to the survival advantage conferred by achievement of complete or partial remission."
01/01/2013 - "Around 6 weeks after this single azacitidine cycle, complete remission-according to international working group criteria-was observed with continuous improvement in peripheral blood counts to normal values, transfusion-independence, normal blast count (< 5 %) with normal morphology and flow cytometry, as well as a normal bone marrow karyotype and no dysplastic stigmata suggestive of a coexisting myelodysplastic syndrome. "
11/01/2010 - "Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. "
10/15/2006 - "Azacitidine administered in the outpatient setting is well tolerated and can induce complete hematological remission in patients with myelodysplastic syndromes (MDS). "
2. lenalidomide (CC 5013)FDA Link
3. Cytarabine (Cytosar-U)FDA LinkGeneric
4. ErythropoietinFDA Link
5. decitabine (5-aza-2'-deoxycytidine)FDA Link
6. Granulocyte Colony-Stimulating Factor (G-CSF)IBA
7. Thalidomide (Thalomid)FDA Link
8. fludarabineIBA
9. Cyclosporine (Ciclosporin)FDA LinkGeneric
10. DNA (Deoxyribonucleic Acid)IBA

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Hematopoietic Stem Cell Transplantation
3. Transplantation (Transplant Recipients)
4. Transplants (Transplant)
5. Bone Marrow Transplantation (Transplantation, Bone Marrow)